Shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) traded down 5.6% during mid-day trading on Monday . The stock traded as low as $4.05 and last traded at $4.05, with a volume of 149,384 shares. The stock had previously closed at $4.29.

Several analysts have issued reports on the company. Roth Capital restated a “buy” rating and set a $17.00 price objective on shares of Vascular Biogenics in a report on Tuesday. Zacks Investment Research upgraded Vascular Biogenics from a “sell” rating to a “hold” rating in a report on Thursday, July 14th. HC Wainwright began coverage on Vascular Biogenics in a report on Tuesday, June 28th. They set a “buy” rating and a $11.00 price objective on the stock. Chardan Capital reiterated a “buy” rating on shares of Vascular Biogenics in a report on Tuesday, June 7th. Finally, Piper Jaffray Cos. reiterated a “buy” rating and issued a $14.00 target price on shares of Vascular Biogenics in a report on Tuesday, June 7th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $15.50.

The firm’s 50-day moving average price is $4.14 and its 200 day moving average price is $3.70. The firm’s market cap is $96.77 million.

Vascular Biogenics (NASDAQ:VBLT) last posted its quarterly earnings results on Monday, August 15th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.09. Analysts forecast that Vascular Biogenics Ltd. will post ($0.75) earnings per share for the current fiscal year.

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.